The Pacific Northwest has a substantial population of HIV- infected individuals who remain at high risk for the development of AIDS-associated neoplasms. Although an AIDS Clinical Trials Unit (ACTU) is present in Seattle, Washington and a community treatment consortium if present in Portland, Oregon, there is not currently in place a mechanism to enroll patients with AIDS- malignances in novel phase I and phase II national clinical trials. This grant is written with the goal of receiving NCI funding to develop an AIDS-malignancy consortium (AMC) site at the Virginia Mason Medical Center (VMMC). The specific purpose of the VNNC-AMC site is to: 1. Share the expertise in the evaluation and treatment of HIV-associated malignancies with researchers in various disciplines. 2. Conduct joint exploratory phase I and phase II clinical trials of novel agents and to help develop innovative approaches for the treatment of AIDS-associated malignancies. 3. Recruit 30 patients per year into AMC sponsored clinical trials with a particular goal of reaching out to women and minorities who are often not represented in clinical trials. 4. Collect tissue samples and relevant biological fluids for laboratory studies and donation for the AMC tumor bank from consenting subjects with AIDS-associated malignancies. 5. Assist the AMC and the NCI clinical trials cooperative groups and the NIAID ACTUs in the development and implementation of phase III studies if initial efforts of the AMC consortium are successful.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA083118-04
Application #
6522328
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (M1))
Program Officer
Bhatia, Kishor
Project Start
1999-09-10
Project End
2004-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
4
Fiscal Year
2002
Total Cost
$79,377
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101
Mani, Deepthi; Haigentz Jr, Missak; Aboulafia, David M (2012) Lung cancer in HIV Infection. Clin Lung Cancer 13:6-13
Lechowicz, Maryjo; Dittmer, Dirk P; Lee, Jeannette Y et al. (2009) Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis 49:1946-9
Lin, Lan; Lee, Jeannette Y; Kaplan, Lawrence D et al. (2009) Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 27:2496-502
Spitzer, Thomas R; Ambinder, Richard F; Lee, Jeannette Y et al. (2008) Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 14:59-66
Dezube, Bruce J; Krown, Susan E; Lee, Jeannette Y et al. (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 24:1389-94
Kaplan, Lawrence D; Lee, Jeannette Y; Ambinder, Richard F et al. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-43
Noy, Ariela; Scadden, David T; Lee, Jeannette et al. (2005) Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-8